AAD 2022

New Developments and Unmet Needs in Dermatology

What’s Hot in Rare Diseases

Add-on apremilast may improve recalcitrant dermatomyositis

Presented By

Prof. Carole Bitar, Tulane University School of Medicine, USA

Trial

Phase 2

Conference

AAD 2022

17 May, 2022 12:03

Could dupilumab put an end to the therapeutic draught in prurigo nodularis?

Presented By

Prof. Gil Yosipovitch, University of Miami, USA

Trial

Phase 3, LIBERTY-PN PRIME 2

Conference

AAD 2022

17 May, 2022 11:59

Fungal skin infections in children: A diagnosis to keep in mind

Presented By

Prof. A. Yasmine Kirkorian, George Washington University School of Medicine, USA

Conference

AAD 2022

17 May, 2022 11:54

Innovative gel speeds up clearance of molluscum contagiosum lesions

Presented By

Prof. John Browning, University of Texas, USA

Trial

Phase 3, B-SIMPLE4

Conference

AAD 2022

17 May, 2022 11:51

JAK inhibition offers promising treatment prospects for uncommon dermatoses

Presented By

Prof. Matthew Vesely, Yale School of Medicine, USA

Conference

AAD 2022

17 May, 2022 11:48

JAK inhibitors may offer a new horizon in the treatment of sarcoidosis

Presented By

Prof. William Damsky, Yale School of Medicine, USA

Conference

AAD 2022

17 May, 2022 11:12

Psoriasis: State of the Art

New insights into psoriasis comorbidity

Presented By

Prof. Joel Gelfand, University of Pennsylvania, USA

Conference

AAD 2022

17 May, 2022 12:12

Long-term psoriasis treatment with bimekizumab results in maintained efficacy

Presented By

Prof. Kenneth Gordon, Medical College of Wisconsin, USA

Conference

AAD 2022

17 May, 2022 12:09

Novel developments in topical psoriasis therapy

Presented By

Prof. April Armstrong, University of Southern California Keck School of Medicine, USA

Trial

Phase 3, PSOARING; PSO-LONG

Conference

AAD 2022

17 May, 2022 12:06

Atopic Dermatitis: Novel Agents Enter the Stage

JAK inhibitors in AD: Setting the efficacy bar even higher

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Trial

Measure Up 1; JADE Mono-1; JADE Compare; Heads Up

Conference

AAD 2022

17 May, 2022 12:21

Lebrikizumab treatment leads to encouraging outcomes in multiple traits of AD

Presented By

Prof. Jonathan Silverberg, George Washington University School of Medicine, USA

Trial

Phase 3, ADvocate 1; ADvocate 2

Conference

AAD 2022

17 May, 2022 12:18

Novel IL-4/IL-13 blocker shows high efficacy with only modest conjunctivitis signal

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, USA

Conference

AAD 2022

17 May, 2022 12:15

Posters

Inpatient dermatologic therapy is linked to lower mortality and readmission rates

Presented By

Dr Pranav Puri

Conference

AAD 2022

18 May, 2022 12:31

AD treatment during the pandemic: dupilumab does not raise COVID-19 infection risk

Presented By

Dr Brian Rankin, University of Calgary, Canada

Trial

Cohort study

Conference

AAD 2022

18 May, 2022 12:27

Upadacitinib: Fast and more pronounced skin improvement in AD patients

Presented By

Prof. Jonathan Silverberg, George Washington University School of Medicine, USA

Trial

Phase 3, Heads Up

Conference

AAD 2022

17 May, 2022 12:35

Dermatology diseases need the highest doses of biologics

Presented By

Dr Charlotte Greif, Beth Israel Deaconess Medical Center, USA

Conference

AAD 2022

17 May, 2022 12:24